Eli Lilly vs. Novo Nordisk: Which Diabetes and Weight Loss Giant Reigns Supreme?

Eli Lilly and Novo Nordisk are competing in the weight loss market, with Lilly's Zepbound surpassing Novo Nordisk's Wegovy in quarterly sales. Lilly's diversified portfolio, including Verzenio and Taltz, generates over $1 billion in annual sales, while Novo Nordisk's revenue comes primarily from diabetes and weight loss products. Lilly's retatrutide candidate also posted a 28.7% mean weight loss, making it a strong contender in the market.